Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 09:24 ET | Source: Trethera Corporation

FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers

Creates platform for precision dosing, companion diagnostics, streamlined development, and broader use across cancer and autoimmune diseases.
July 30, 2025 07:40 ET | Source: Research and Markets

2 Day FDA (Food and Drug Administration) Drug Approval Process Training Course | Stay Ahead with Insights into IND, NDA, ANDA, and 505(b)(2) Submissions (ONLINE EVENT: October 7-8, 2025)

Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" training has been added to ResearchAndMarkets.com's offering. The US...
June 03, 2025 09:10 ET | Source: Trethera Corporation

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045

Global exclusive agreement expands patent coverage for compound structures and autoimmune uses across major pharmaceutical markets
June 03, 2025 06:00 ET | Source: Priothera

Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen

Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing...
May 21, 2025 09:12 ET | Source: Trethera Corporation

Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board

Trethera enlists leading expert in demyelinating diseases to advance TRE-515, a first-in-class drug with FDA Orphan Drug status for ADEM and optic neuritis
May 06, 2025 03:00 ET | Source: Priothera

Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)

Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AML Saint-Louis, France and Dublin, Ireland – 6th May 2025– Priothera Ltd., a...
April 23, 2025 12:59 ET | Source: AB Science

La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue

COMMUNIQUE DE PRESSE LA MOLECULE AB8939 OBTIENT LA DESIGNATION DE MEDICAMENT ORPHELIN DANS L’UNION EUROPEENNE AUPRES DE L’AGENCE EUROPEENNE DES MEDICAMENTS (EMA) DANS LE TRAITEMENT DE LA LEUCEMIE...
April 23, 2025 12:59 ET | Source: AB Science

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB...
April 08, 2025 05:12 ET | Source: Research and Markets

Rare Diseases Treatment Market to Surpass US$36.5 Billion by 2030 Driven by Precision Medicine Breakthroughs | Asia-Pacific Leads in Rare Disease Drug Development with Fast-Tracked Regulatory Reforms

Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Rare Diseases Treatment Market by Drug Type (Biological Drugs, Non-Biological Drugs), Therapeutic Area (Cancer, Cardiovascular Conditions, Endocrine...
March 31, 2025 09:30 ET | Source: Trethera Corporation

Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE 515

LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through...

Next Page keyboard_arrow_right